Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 328

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer

Open access
Setlur, Sunita R., Mertz, Kirsten D., Hoshida, Yujin, Demichelis, Francesca, Lupien, Mathieu, Perner, Sven, Sboner, Andrea, Pawitan, Yudi, Andrén, Ove, Johnson, Laura A., Tang, Jeff, Adami, Hans-Olov, Calza, Stefano, Chinnaiyan, Arul M., Rhodes, Daniel, Tomlins, Scott, Fall, Katja, Mucci, Lorelei A., Kantoff, Philip W., Stampfer, Meir J., Andersson, Swen-Olof, Varenhorst, Eberhard, Johansson, Jan-Erik, Brown, Myles, Golub, Todd R., Rubin, Mark A.·2008·JNCI: Journal of the National Cancer Institute

Abstract

BACKGROUND: The majority of prostate cancers harbor gene fusions of the 5'-untranslated region of the androgen-regulated transmembrane protease serine 2 (TMPRSS2) promoter with erythroblast transformation-specific transcription factor family members. The common fusion between TMPRESS2 and v-ets erythroblastosis virus E26 oncogene homolog (avian) (ERG) is associated with a more aggressive clinical phenotype, implying the existence of a distinct subclass of prostate cancer defined by this fusion. METHODS: We used complementary DNA-mediated annealing, selection, ligation, and extension to determine the expression profiles of 6144 transcriptionally informative genes in archived biopsy samples from 455 prostate cancer patients in the Swedish Watchful Waiting cohort (1987-1999) and the United States-based Physicians(') Health Study cohort (1983-2003). A gene expression signature for prostate cancers with the TMPRSS2-ERG fusion was determined using partitioning and classification models and used in computational functional analysis. Cell proliferation and TMPRSS2-ERG expression in androgen receptor-negative (NCI-H660) prostate cancer cells after treatment with vehicle or estrogenic compounds were assessed by viability assays and quantitative polymerase chain reaction, respectively. All statistical tests were two-sided. RESULTS: We identified an 87-gene expression signature that distinguishes TMPRSS2-ERG fusion prostate cancer as a discrete molecular entity (area under the curve = 0.80, 95% confidence interval [CI] = 0.792 to 0.81; P < .001). Computational analysis suggested that this fusion signature was associated with estrogen receptor (ER) signaling. Viability of NCI-H660 cells decreased after treatment with estrogen (viability normalized to day 0, estrogen vs vehicle at day 8, mean = 2.04 vs 3.40, difference = 1.36, 95% CI = 1.12 to 1.62) or ERbeta agonist (ERbeta agonist vs vehicle at day 8, mean = 1.86 vs 3.40, difference = 1.54, 95% CI = 1.39 to 1.69) but increased after ERalpha agonist treatment (ERalpha agonist vs vehicle at day 8, mean = 4.36 vs 3.40, difference = 0.96, 95% CI = 0.68 to 1.23). Similarly, expression of TMPRSS2-ERG decreased after ERbeta agonist treatment (fold change over internal control, ERbeta agonist vs vehicle at 24 hours, NCI-H660, mean = 0.57- vs 1.0-fold, difference = 0.43-fold, 95% CI = 0.29- to 0.57-fold) and increased after ERalpha agonist treatment (ERalpha agonist vs vehicle at 24 hours, mean = 5.63- vs 1.0-fold, difference = 4.63-fold, 95% CI = 4.34- to 4.92-fold). CONCLUSIONS: TMPRSS2-ERG fusion prostate cancer is a distinct molecular subclass. TMPRSS2-ERG expression is regulated by a novel ER-dependent mechanism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djn150

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 328

Metadata

Authors
Setlur, S. R., Mertz, K. D., Hoshida, Y., Demichelis, F., Lupien, M., Perner, S., Sboner, A., Pawitan, Y., Andrén, O., Johnson, L. A., Tang, J., Adami, H.-O., Calza, S., Chinnaiyan, A. M., Rhodes, D., Tomlins, S., Fall, K., Mucci, L. A., Kantoff, P. W., Stampfer, M. J., Andersson, S.-O., Varenhorst, E., Johansson, J.-E., Brown, M., Golub, T. R., & Rubin, M. A.
Venue
JNCI: Journal of the National Cancer Institute
Published
2008-06-04
Volume
100
Issue
11
Pages
815-825
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2151726393
Cited by
328
References
4
FWCI
27.82
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer. https://app.cochat.ai/papers/10.1093/jnci/djn150
The paper
Setlur, S. R., Mertz, K. D., Hoshida, Y., Demichelis, F., Lupien, M., Perner, S., Sboner, A., Pawitan, Y., Andrén, O., Johnson, L. A., Tang, J., Adami, H.-O., Calza, S., Chinnaiyan, A. M., Rhodes, D., Tomlins, S., Fall, K., Mucci, L. A., Kantoff, P. W., . . . Rubin, M. A. (2008). Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djn150

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.